U.s. fda extends review of biologics license application for regen-cov® (casirivimab and imdevimab) for treatment and prophylaxis of covid-19

Regeneron continues to progress its next generation antibodies, and has initiated a first-in-human trial tarrytown, n.y. , april 14, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the u.s. food and drug administration (fda) has extended by three months its review of the biologics license application (bla) for regen-cov® (casirivimab and imdevimab) to treat covid-19 in non-hospitalized patients and as prophylaxis in certain individuals.
REGN Ratings Summary
REGN Quant Ranking